Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kB pathways

Renal Failure

Volumn 31, Issue 5, 2009, Pages 382-392

  Ozbek, Emin ^a   Cekmen, Mustafa ^b   Ilbey, Yusuf Ozlem ^a   Simsek, Abdulmuttalip ^a   Polat, Emre Can ^a   Somay, Adnan ^c  

^a Bezm i Alem Valide Sultan Vakif Gureba Research and Education Hospital   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c Bezm i Alem Valide Sultan Vakif Gureba Research and Education Hospital   (Turkey)

Author keywords

Gentamicin; Inducible nitric oxide synthase (iNOS); Nephrotoxicity; Nuclear factor kappa B (NF kB); P38 MAPK (mitogen activated protein kinase); Statin

Indexed keywords

ATORVASTATIN; CREATININE; GENTAMICIN; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENZYME INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY DYSFUNCTION; KIDNEY TUBULE NECROSIS; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL; TRANSCRIPTION REGULATION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; FREE RADICAL SCAVENGERS; GENTAMICINS; HEPTANOIC ACIDS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION TESTS; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; NITRIC OXIDE; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROBABILITY; PYRROLES; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 70849129763     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220902835863     Document Type: Article

References (66)

1. Reiter RJ, Tan D, Sainz RM, Mayo JC, Lopez BS. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-1321.
2. Pedraza-Chaverrí J, González-Orozco AE, Maldonado PD, Barrera D, Medina-Campos ON, Hernández-Pando R. Diallyl disulfide ameliorates gentamicin-induced oxidative stress and nephropathy in rats. Eur J Pharmacol. 2003;473:71-78. (Pubitemid 36851630)
3. Edson RS, Terrell CL. The aminoglycosides. Mayo Clinic proceedings. 1999;74:519-528.
4. Banday AA, Farooq N, Priyamvada S, Yusufi AN, Khan F. Time-dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci. 2008;82:450-459.
5. Polat A, Parlakpinar H, Tasdemir S, Colak C, Vardi N, Ucar M, Emre MH, Acet A. Protective role of aminoguanidine on gentamicin-induced acute renal failure in rats. Acta Histochem. 2006;108:365-371.
6. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: Some recent research. Food Chem Toxicol. 2003;41:1447-1452.
7. Priuska EM, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol. 1995;50:1749-1752.
8. Yanagida C, Ito K, Komiya I, Horie T. Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem Biol Interact. 2004;148:139-147.
9. Samadian T, Dehpour AR, Amini S, Nouhnejad P. Inhibition of gentamicin-induced nephrotoxicity by lithium in rat. Histol Histopathol. 1993;139-147.
10. Tugcu V, Ozbek E, Tasci AI, Kemahli E, Somay A, Bas M. Selective nuclear factor kappa-B inhibitors, pyrolidium dithiocarbamate and sulfasalazine, prevent the nephrotoxicity induced by gentamicin. BJU Int. 2006;98:680-686.
11. Volpini RA, Balbi AP, Costa RS, Coimbra TM. Increased expression of p38 mitogen-activated protein kinase is related to the acute renal lesions induced by gentamicin. Braz J Med Biol Res. 2006;39:817-823.
12. Volpini RA, Costa RS, da Silva CG, Coimbra TM. Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin. Nephron Physiol. 2004;98:97-106.
13. Bokemeyer D, Ostendorf T, Kunter U, Lindemann M, Kramer HJ, Floege J. Differential activation of mitogenactivated protein kinases in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2000;11:232-240.
14. Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717-726.
15. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol. 2003;14:338-351.
16. Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ. Inhibition of p38 mitogenactivated protein kinase augments progression of remnant kidney model by activating the ERK pathway. Am J Pathol. 2004;164:477-485.
17. Bokemeyer D, Sorokin A, Dunn MJ. Multiple intracellular MAP kinase signaling cascades. Kidney Int. 1996;49:1187-1198.
18. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signalregulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998;18:1633-1641.
19. Da Silva J, Pierrat B, Mary JL, Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J Biol Chem. 1997;272:28373-28380.
20. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162:196-203.
21. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072:129-157.
22. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
23. Blackwell TS, Christman JW. The role of nuclear factorkappa B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997;17:3-9.
24. Pahan K, Sheikh FG, Namboodiri AM, Singh I. N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic Biol Med. 1998;24:39-48.
25. Lee JK, Choi SS, Won JS, Suh HW. The regulation of inducible nitric oxide synthase gene expression induced by lipopolysaccharide and tumor necrosis factor-alpha in C6 cells: Involvement of AP-1 and NFkappaB. Life Sci. 2003;73:595-609.
26. Ghaznavi R, Kadkhodaee M. Comparative effects of selective and non-selective nitric oxide synthase inhibition in gentamicin- induced rat nephrotoxicity. Arch Toxicol. 2007; 81:453-457.
27. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19:26-37.
28. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998;138:271-280.
29. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333:621-627.
30. Plutzky J, Ridker PM. Statins for stroke: The second story? Circulation. 2001;103:348-350.
31. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation. 1997;96:1398-1402.
32. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143-180.
33. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune response. Ann Rev Immunol. 1998;16:225-260.
34. Jiang JL, Wang S, Li NS, Zhang XH, Deng HW, Li YJ. The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochem Cell Biol. 2007;85:66-77.
35. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003;58:186-195.
36. Erdem A, Gündogan NU, Usubütün A, Kilinç K, Erdem SR, Kara A, et al. The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats. Nephrol Dial Transplant. 2000;15:1175-1182.
37. Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: A biochemical, histological and electrophysiological study. Br J Pharmacol. 2006;149:909-919.
38. Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun. 2005;25:258-263.
39. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993;39:2522-2528.
40. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582:67-78. (Pubitemid 9065588)
41. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
42. Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1999;268:142-151.
43. Houghton DC, Plamp CE, DeFehr JM, Bennett WM, Porter G, Gilgert D. Gentamicin and tobramicin nephrotoxicity. A morphologic and functional comparison in the rat. Am J Pathol. 1978;93:137-152.
44. Moochhala S, Chhatwal VJ, Chan ST, Ngoi SS, Chia YW, Rauff A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis. 1996;17:1171-1174.
45. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Britti D, et al. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol. 2002;450:67-76.
46. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail. 1999;21:433-442.
47. Banday AA, Farooq N, Priyamvada S, Yusufi AN, Khan F. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci. 2008; 82:450-459.
48. Polat A, Parlakpinar H, Tasdemir S, Colak C, Vardi N, Ucar M, et al. Protective role of aminoguanidine on gentamicininduced acute renal failure in rats. Acta Histochem. 2006;108:365-371.
49. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: Some recent research. Food Chem Toxicol. 2003;41:1447-1452.
50. Volpini RA, Balbi AP, Costa RS, Coimbra TM. Increased expression of p38 mitogen-activated protein kinase is related to the acute renal lesions induced by gentamicin. Braz J Med Biol Res. 2006;39:817-823.
51. Jang J, Park EY, Seo SI, Hwang TK, Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int. 2006;98:435-439.
52. Stepie K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep. 2005;57:561-569.
53. Juan SH, Chen CH, Hsu YH, Hou CC, Chen TH, Lin H, et al. Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin. Nephrol Dial Transplant. 2007;22:732-739.
54. Volpini RA, Balbi AP, Costa RS, Coimbra TM. Increased expression of p38 mitogenactivated protein kinase is related to the acute renal lesions induced by gentamicin. Braz J Med Biol Res. 2006;39:817-823.
55. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
56. Ghaznavi R, Kadkhodaee M. Comparative effects of selective and non-selective nitric oxide synthase inhibition in gentamicin-induced rat nephrotoxicity. Arch Toxicol. 2007;81:453-457.
57. Klahr S. The role of L-arginine in hypertension and nephrotoxicity. Curr Opin Nephrol Hypertens. 1998;7:547-550.
58. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, et al. Blockade of p38 alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol. 2003;14:338-351.
59. Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2:717-726.
60. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162:196-203.
61. Ortego M, Gómez-Hernández A, Vidal C, Sánchez- Galán E, Blanco-Colio LM, Martín-Ventura JL, et al. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol. 2005;45:468-475.
62. Gu L, Ni Z, Qian J, Tomino Y. Pravastatin inhibits carboxymethyllysine- induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol. 2007;106:1-10.
63. Houghton DC, English J, Bennett WM. Chronic tubulointerstitial nephritis and renal insufficiency associated with longterm "subtherapeutic" gentamicin. J Lab Clin Med. 1988;112:694-703.
64. Fuhr J, Kaczmarczyk J, Kruttgen CD. A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics. Klin Wochenschr. 1955;33:729-730.
65. Ozbek E, Turkoz Y, Sahna E, Ozugurlu F, Mizrak B, Ozbek M. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU International. 2000;85:742-746.
66. Iseri S, Ercan F, Gedik N, Yüksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology. 2007;230:256-264.